New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2013
13:09 EDTTIVO, PLCE, GME, HUM, ACN, BIIBOptions with decreasing implied volatility: TIVO PLCE GME HUM ACN BIIB
News For TIVO;PLCE;GME;HUM;ACN;BIIB From The Last 14 Days
Check below for free stories on TIVO;PLCE;GME;HUM;ACN;BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 15, 2014
16:04 EDTTIVOTiVo files $200M in convertible senior notes to fund buybacks
Subscribe for More Information
09:53 EDTGMEGameStop intends to exit Spanish market through partial sale of store locations
Subscribe for More Information
09:52 EDTGMEGameStop intends to exit Spanish market through partial sale of store locations
08:01 EDTBIIBAlnylam names Karen Anderson as SVP, Chief Human Resources Officer
Subscribe for More Information
September 12, 2014
12:04 EDTHUMHumana management to meet with Jefferies
Subscribe for More Information
07:32 EDTBIIBBiogen, AbbVie announce ZINBRYTA DECIDE Phase 3 study results
Biogen (BIIB) and AbbVie (ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA, dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis compared to AVONEX. These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis. Patients on ZINBRYTA demonstrated a statistically significant 45% reduction in annualized relapse rate compared to patients treated with AVONEX. Based on the efficacy and safety data from the ZINBRYTA clinical development program, Biogen Idec and AbbVie plan to file marketing applications for ZINBRYTA with regulatory authorities during 1H15.
07:19 EDTGMEConsoles lead video game sales up 8% in August, Bloomberg reports
Subscribe for More Information
05:36 EDTGMEAugust NPD video game software sales fell 21%, says Piper Jaffray
Piper Jaffray says August NPD video game software sales fell 21% year-over-year. The firm continues to expect growth beginning in late 2014 and recommends using any weakness in shares of GameStop (GME), Electronic Arts (EA), Activision Blizzard (ATVI) and Take-Two (TTWO) as a buying opportunity.
05:30 EDTTIVOTiVo launches full EU sales, support organization
TiVo announced it expanded its existing European footprint to now include sales, marketing and account management staff in offices in Austria, England, the Netherlands, Poland and Spain specifically dedicated to personalized video discovery solutions. This expansion builds on the continued success of TiVo delivering advanced TV services with European cable operator partners including ComHem in Sweden, Ono in Spain, and Virgin in the UK. Following TiVo's acquisition in February of Digitalsmiths, the company delivers a unified, personalized experience instantly connecting consumers with the most relevant video content available, at any time, on any screen.
September 11, 2014
17:27 EDTTIVOBroadcom powers new TiVo Ultra HD set-top box solution
Subscribe for More Information
10:49 EDTTIVOHigh option volume stocks
Subscribe for More Information
07:31 EDTBIIBBiogen announces 5-year results from TECFIDERA ENDORSE Phase 3 study
Subscribe for More Information
07:31 EDTBIIBBiogen announces new data from Plegridy Phase 3 ADVANCE trial
Biogen Idec announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY were maintained in people with relapsing forms of multiple sclerosis beyond the first year of the study. These results were presented at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis in Boston. Post-hoc analyses from the two-year, Phase 3 ADVANCE clinical trial confirm that PLEGRIDY’s positive effects on reducing disease activity and disability progression were maintained in year two of the study. A significantly higher proportion of patients taking PLEGRIDY during both years of the study experienced no evidence of disease activity – defined as the absence of clinical and MRI disease activity over two years of treatment – compared to those who switched to PLEGRIDY from placebo. Also, those treated with PLEGRIDY for both years of the study had significant reductions in the risk of 24-week confirmed disability progression compared to patients treated with placebo during the first year. In addition, new data from the second year of ADVANCE show that patients who took PLEGRIDY throughout the study experienced statistically significant improvements in clinical and MRI outcomes – including annualized relapse rate, risk of relapse, risk of 24-week confirmed disability progression, and number of brain lesions – when compared to those who switched to PLEGRIDY after taking placebo for the first year. This new data also showed that the safety profile of PLEGRIDY was consistent between years one and two of the study.
September 10, 2014
11:38 EDTGMEGameStop achieved high share of Destiny sales, says BofA/Merrill
Activision (ATVI) announced that it sold more than $500M of Destiny on its first day, making it the biggest new video game franchise launch in history. BofA/Merrill believes GameStop (GME) had a very high share of Destiny sales and expects further clarity in the coming months. The analyst continues to believe GameStop is leveraged to momentum in the console cycle and believes competitive threats from full game downloads id overblown. Shares of GameStop are Buy rated with a $56 price target.
08:51 EDTGMEGameStop volatility at low end of historic range
GameStop September call option implied volatility is at 31, November is at 33, January is at 36; compared to it 26-week average of 41 according to Track Data, suggesting decreasing price movement.
08:42 EDTHUMHumana says all 2015 Medicare Advantage, PDP offerings approved
Subscribe for More Information
07:31 EDTGMEGameStop, Alliance Data announce branded private label credit card program
GameStop Corporation (GME) and Alliance Data Systems Corporation (ADS) announced the introduction of a GameStop-branded private label credit card program. Under the terms of the long-term agreement, Alliance Data’s Retail Services business, which manages more than 135 private label and co-brand credit programs, will deliver a customized loyalty-driven private label credit program designed to further enrich GameStop’s relationship with its more than 28 million members of the successful PowerUp Rewards loyalty program. The new GameStop PowerUp Rewards Credit Card will provide cardholders with convenience and benefits exclusive to account holders, including being able to make purchases with the card in-store and online, promotional financing for larger purchases, online and mobile platform card management and payment services, as well as no annual fee and exclusive offers for savings throughout the year. Upon the opening of an account, PowerUp Rewards Pro members will receive a one-time award of 15,000 bonus points, and PowerUp Rewards Basic members will receive a one-time award of 5,000 bonus points.
September 8, 2014
09:27 EDTBIIBLeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.
08:03 EDTACNGeneral Electric, Accenture launch Intelligent Pipeline Solution
Subscribe for More Information
07:15 EDTBIIBIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use